IDSA ' s approach the Limited Population Antibacterial Drug would speed patients ' access to new , lifesaving antibiotics by allowing the Food and Drug Administration to approve them for narrow use based on smaller clinical trials than required for more widely used antibiotics . Under LPAD , drug companies will still have to show that a drug ' s benefits outweigh the risks in patients with serious infections . It ' s an idea modeled after the successful Orphan Drug Program , which encourages the development of drugs for rare diseases .
